Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The investigation of human cerebrospinal fluid exosome in spinal cord injury
Dallas L. Sheinberg, Haichao Wei, Joseph S. Withrow, Farshad Homayouni Moghadam, Chia-Chen Lu, Jyotirmoy Rakshit, Jennifer Zaragoza, John R. Williams, Wen Li, Jacques J. Morcos, Jia Qian Wu
Dallas L. Sheinberg, Haichao Wei, Joseph S. Withrow, Farshad Homayouni Moghadam, Chia-Chen Lu, Jyotirmoy Rakshit, Jennifer Zaragoza, John R. Williams, Wen Li, Jacques J. Morcos, Jia Qian Wu
View: Text | PDF
Research Article Cell biology Neuroscience

The investigation of human cerebrospinal fluid exosome in spinal cord injury

  • Text
  • PDF
Abstract

Spinal cord injury (SCI) leads to severe neurological and functional impairments, yet reliable biomarkers for assessing injury severity and predicting recovery remain limited. Cerebrospinal fluid (CSF) is in direct contact with the central nervous system and provides a valuable source for detecting molecular changes after SCI. Although exosomal microRNAs (miRNAs) and proteins are increasingly recognized as mediators of intercellular communication, the role of human CSF exosomes in SCI has not been systematically investigated. To identify exosome-based biomarkers and potential therapeutic targets, we analyzed CSF and serum exosomes from patients with acute SCI using RNA sequencing and proteomic profiling. Weighted gene co-expression network analysis identified 6 gene modules significantly associated with injury severity and neurological recovery at 3 months. Proteomic analysis revealed a 5-protein panel that distinguished complete from incomplete SCI and a 4-protein panel that predicted neurological improvement. Additionally, 15 CSF-specific and 9 serum-specific exosomal miRNAs were identified independent of injury severity. Among 10 tested miRNAs associated with neurological recovery, 7 regulated astrocyte proliferation, and 6 promoted neurite extension and synapse formation. Overall, this study provides a comprehensive characterization of CSF exosomal miRNAs and proteins in human SCI and identifies molecular signatures associated with injury severity and recovery.

Authors

Dallas L. Sheinberg, Haichao Wei, Joseph S. Withrow, Farshad Homayouni Moghadam, Chia-Chen Lu, Jyotirmoy Rakshit, Jennifer Zaragoza, John R. Williams, Wen Li, Jacques J. Morcos, Jia Qian Wu

×

Figure 8

qPCR analysis of hsa-miR-7111-3p expression in patient CSF exosomes.

Options: View larger image (or click on image) Download as PowerPoint
qPCR analysis of hsa-miR-7111-3p expression in patient CSF exosomes.
hsa...
hsa-miR-7111-3p expression level was higher in the non-improvement patient group compared with the improvement patient group. (A) Day 1 after injury (improvement patients, n = 4; non-improvement patients, n = 4). (B) Day 3/5 after injury represents pooled samples from days 3 and 5 (improvement patients, n = 4; non-improvement patients, n = 5). (C) Day 1/3/5 after injury represents pooled samples from days 1, 3, and 5 (improvement patients, n = 5; non-improvement patients, n = 5). Results are expressed as mean ± SEM for each group. *P < 0.05, **P < 0.01 (1-tailed independent t test).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts